UA5210U - Способ лечения пиелонефрита у беременных женщин - Google Patents
Способ лечения пиелонефрита у беременных женщин Download PDFInfo
- Publication number
- UA5210U UA5210U UA20040806452U UA2004806452U UA5210U UA 5210 U UA5210 U UA 5210U UA 20040806452 U UA20040806452 U UA 20040806452U UA 2004806452 U UA2004806452 U UA 2004806452U UA 5210 U UA5210 U UA 5210U
- Authority
- UA
- Ukraine
- Prior art keywords
- pyelonephritis
- pregnant women
- blood
- therapy
- detoxification
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 23
- 206010037596 Pyelonephritis Diseases 0.000 title claims abstract description 13
- 238000001784 detoxification Methods 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940124350 antibacterial drug Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 14
- 238000002560 therapeutic procedure Methods 0.000 abstract description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 2
- 230000035935 pregnancy Effects 0.000 description 11
- 210000003754 fetus Anatomy 0.000 description 10
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 8
- 230000005855 radiation Effects 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000005713 exacerbation Effects 0.000 description 4
- 230000035987 intoxication Effects 0.000 description 4
- 231100000566 intoxication Toxicity 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010056254 Intrauterine infection Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001447 compensatory effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 description 2
- 240000002900 Arthrospira platensis Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000006368 chronic pyelonephritis Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000002616 plasmapheresis Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 229940082787 spirulina Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010016855 Foetal distress syndrome Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 206010037597 Pyelonephritis acute Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000001555 acute pyelonephritis Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000004656 cell transport Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 231100000508 hormonal effect Toxicity 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- RJIWZDNTCBHXAL-UHFFFAOYSA-N nitroxoline Chemical compound C1=CN=C2C(O)=CC=C([N+]([O-])=O)C2=C1 RJIWZDNTCBHXAL-UHFFFAOYSA-N 0.000 description 1
- 229960005131 nitroxoline Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006385 ozonation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000258 photobiological effect Effects 0.000 description 1
- 230000016412 positive regulation of cytokine production Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000004717 pyruvic acids Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 230000003202 urodynamic effect Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Способ лечения пиелонефрита у беременных женщин включает в себя применение антибактериальных препаратов и иммуностимуляцию с детоксикацией организма. В качестве противобактериального и иммуностимулирующего средства внутривенно вводят озонированный физраствор, чередуя эту процедуру с ультрафиолетовым облучением аутологичной крови. Детоксикацию организма проводят путем энтеросорбции.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20040806452U UA5210U (ru) | 2004-08-02 | 2004-08-02 | Способ лечения пиелонефрита у беременных женщин |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA20040806452U UA5210U (ru) | 2004-08-02 | 2004-08-02 | Способ лечения пиелонефрита у беременных женщин |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA5210U true UA5210U (ru) | 2005-02-15 |
Family
ID=74494013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040806452U UA5210U (ru) | 2004-08-02 | 2004-08-02 | Способ лечения пиелонефрита у беременных женщин |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA5210U (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2635083C1 (ru) * | 2016-12-08 | 2017-11-08 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ комплексного лечения эндогенного увеита, сопровождающегося макулярным отеком |
-
2004
- 2004-08-02 UA UA20040806452U patent/UA5210U/ru unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2635083C1 (ru) * | 2016-12-08 | 2017-11-08 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ комплексного лечения эндогенного увеита, сопровождающегося макулярным отеком |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bocci et al. | The clinical application of ozonetherapy | |
| WO1994001099A1 (en) | Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions | |
| Markham et al. | Peritoneal dialysis in quinine sulfate intoxication | |
| UA5210U (ru) | Способ лечения пиелонефрита у беременных женщин | |
| Nugroho et al. | Surgical management of necrotizing fasciitis due to odontogenic infection with sepsis: case report | |
| RU2771856C1 (ru) | Способ лечения неосложненного некротизирующего энтероколита у новорожденных с бактериальной инфекцией и при подозрении на наличие внутриутробной инфекции | |
| UA14550U (en) | Method for treating renal infection in pregnant patients and parturient women | |
| UA10295U (ru) | Способ лечения пиелонефрита при беременности | |
| US20100316727A1 (en) | Treatment of inflammatory disorders with ozone | |
| RU2742341C1 (ru) | Способ лечения хронического генерализованного пародонтита | |
| RU2809542C1 (ru) | Способ сопроводительной терапии при хирургическом лечении патологических и застарелых переломов | |
| RU2704470C1 (ru) | Способ лечения урогенитального кандидоза с использованием ультразвуковой кавитации и фотохромотерапии | |
| Viebahn-Haensler | Milestones of medical ozone | |
| Persley et al. | Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis | |
| RU2455037C2 (ru) | Способ локальной иммунокоррекции инфекционно-воспалительных заболеваний урогенитального тракта женщин, вызванных микроорганизмами, передаваемыми половым путём | |
| RU2489172C1 (ru) | Способ проведения лечебного дискретного плазмафереза с экстракарпоральной модификацией эритроцитов и лейкоцитов индукторами интерферона, антиоксидантами и протекторами клеток | |
| RU2353344C1 (ru) | Способ лечения больных хроническим пиелонефритом | |
| RU2155037C1 (ru) | Способ лечения хронического урогенитального кандидоза у женщин | |
| RU2321395C1 (ru) | Способ лечения больных акантолитической пузырчаткой | |
| UA10298U (ru) | Способ профилактики и лечения перинатальных осложнений у беременных с пиелонефритом | |
| RU2268717C1 (ru) | Способ лечения эндометрита в послеродовом периоде | |
| RU2609252C1 (ru) | Способ лечения вирусных гепатитов или циррозов печени биоматериалом "Аллоплант" | |
| Bodenham et al. | Infected facial “cysts” and sinuses of dental origin | |
| RU2357773C1 (ru) | Способ лечения гестоза беременных | |
| RU2254865C1 (ru) | Способ лечения урогенитального хламидиоза |